We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
176
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$673K 0.03%
176
-3,321
-95% -$126K
LSTA icon
177
PUT
Lisata Therapeutics
LSTA
$9.29M
$658K 0.03%
7
+2
+40% +$1.94K
NKTR icon
178
Nektar Therapeutics
NKTR
$2.32B
$648K 0.03%
3,368
+23
+0.7% +$4.07K
ALTO icon
179
Alto Ingredients
ALTO
$336M
$604K 0.03%
+39,500
New +$547K
ALNY icon
180
CALL
Alnylam Pharmaceuticals
ALNY
$38.4B
$600K 0.03%
+95
New +$5.65K
ALIM
181
DELISTED
Alimera Sciences
ALIM
$598K 0.03%
6,667
-26,666
-80% -$2.37M
ECYT
182
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
$569K 0.02%
863
-307
-26% -$3.46K
WINT
183
DELISTED
Windtree Therapeutics Inc
WINT
$562K 0.02%
22,547
+285
+1% +$7.29K
EXEL icon
184
Exelixis
EXEL
$14B
$549K 0.02%
162,000
-267,000
-62% -$922K
XOMA
185
PUT
DELISTED
Xoma
XOMA
$547K 0.02%
60
+6
+11% +$520
LSTA icon
186
Lisata Therapeutics
LSTA
$9.29M
$542K 0.02%
+554
New +$539K
MDCO
187
PUT
DELISTED
Medicines Co
MDCO
$535K 0.02%
184
– –
ALIM
188
CALL
DELISTED
Alimera Sciences
ALIM
$533K 0.02%
+59
New +$5.24K
IMNN icon
189
Imunon
IMNN
$6.47M
$521K 0.02%
55
-28
-34% -$250K
ALBO
190
DELISTED
Albireo Pharma Inc
ALBO
$520K 0.02%
+8,020
New +$558K
SGYPW
191
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$515K 0.02%
+389,982
New +$637K
PBYI icon
192
CALL
Puma Biotechnology
PBYI
$399M
$495K 0.02%
75
-437
-85% -$31.1K
NBSE
193
PUT
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$487K 0.02%
+1
New +$3.77K
EPZM
194
CALL
DELISTED
Epizyme, Inc
EPZM
$479K 0.02%
+154
New +$3.63K
GEVO icon
195
Gevo
GEVO
$353M
$478K 0.02%
+93
New +$549K
RXII
196
CALL
DELISTED
GALENA BIOPHARMA INC COM
RXII
$448K 0.02%
1,466
+66
+5% +$20.2K
RXDX
197
DELISTED
Ignyta, Inc.
RXDX
$445K 0.02%
49,000
-292,810
-86% -$2.24M
ENTA icon
198
CALL
Enanta Pharmaceuticals
ENTA
$364M
$440K 0.02%
102
– –
LUMO
199
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$435K 0.02%
18
– –
AMPE
200
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$397K 0.02%
158
+21
+15% +$42.9K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.